Online inquiry

IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG-7221(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14300MR)

This product GTTS-WQ14300MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets ANGPT2&VEGFA gene. The antibody can be applied in Solid tumors, Colorectal Cancer (CRC) Cancers (CRC) Cancer (CRC) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001118887.2; NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 285; 7422
UniProt ID O15123; P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG-7221(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ14300MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1001MR IVTScrip™ mRNA-Anti-SLAMF7, ABBV-383(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABBV-383
GTTS-WQ13647MR IVTScrip™ mRNA-Anti-CD19, RB4v1.2(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA RB4v1.2
GTTS-WQ1421MR IVTScrip™ mRNA-Anti-MUC16, ACA125(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA ACA125
GTTS-WQ13775MR IVTScrip™ mRNA-Anti-MSTN, REGN-1033(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA REGN-1033
GTTS-WQ12777MR IVTScrip™ mRNA-Anti-NOTCH1, OMP-52M51(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA OMP-52M51
GTTS-WQ13967MR IVTScrip™ mRNA-Anti-GP, REGN3470-3471-3479(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA REGN3470-3471-3479
GTTS-WQ8254MR IVTScrip™ mRNA-Anti-PDCD1, HLX10(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA HLX10
GTTS-WQ13023MR IVTScrip™ mRNA-Anti-IFNAR, Peg-IFNA2 R23(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA Peg-IFNA2 R23
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW